First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: Relationship between exposure and dizziness

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 597-604

  Ouellet, D ^a   Sutherland, S ^a   Wang, T ^a   Griffini, P ^b   Murthy, V ^c  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (Italy)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE TRANSPORTER 1; GSK 1018921; NICOTINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; GAIT DISORDER; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN EXPERIMENT; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NORMAL HUMAN; PHOTOPHOBIA; PHOTOPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SMOKING HABIT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VISUAL DISORDER;

ADOLESCENT; ADULT; BENZAMIDES; COHORT STUDIES; CROSS-OVER STUDIES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 80052965562     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.154     Document Type: Article

References (25)

1. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9, 984-997 (2004). (Pubitemid 39524288)
2. Schmidt, C. Development of GlyT1 inhibitors for the treatment of schizophrenia. Schizophr. Res. 117, 114 (2010).
3. Buchanan, R.W. et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593-1602 (2007). (Pubitemid 350069740)
4. Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G. & Javitt, D.C. Highdose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 55, 165-171 (2004). (Pubitemid 38367720)
5. Leiderman, E., Zylberman, I., Zukin, S.R., Cooper, T.B. & Javitt, D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol. Psychiatry 39, 213-215 (1996). (Pubitemid 26072716)
6. Lane, H.Y., Chang, Y.C., Liu, Y.C., Chiu, C.C. & Tsai, G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62, 1196-1204 (2005). (Pubitemid 41586919)
7. Lane, H.Y. et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 63, 9-12 (2008).
8. T sai, G., Lane, H.Y., Yang, P., Chong, M.Y. & Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55, 452-456 (2004). (Pubitemid 38338531)
9. Herdon, H.J., Godfrey, F.M., Brown, A.M., Coulton, S., Evans, J.R. & Cairns, W.J. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 41, 88-96 (2001). (Pubitemid 32607648)
10. Kalinichev, M., Starr, K.R., Teague, S., Bradford, A.M., Porter, R.A. & Herdon, H.J. Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test. Brain Res. 1331, 105-113 (2010).
11. Herdon, H.J., Roberts, J.C., Coulton, S. & Porter, R.A. Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology 59, 558-565 (2010).
12. Kamal, M.A., Smith, D.E., Cook, J., Feltner, D., Moton, A. & Ouellet, D. Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure. J. Pharm. Sci. 99, 3628-3641 (2010).
13. Kowalski, K.G., McFadyen, L., Hutmacher, M.M., Frame, B. & Miller, R. A two-part mixture model for longitudinal adverse event severity data. J. Pharmacokinet. Pharmacodyn. 30, 315-336 (2003). (Pubitemid 38096186)
14. Mould, D., Chapelsky, M., Aluri, J., Swagzdis, J., Samuels, R. & Granett, J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin. Pharmacol. Ther. 69, 210-222 (2001). (Pubitemid 32382503)
15. Ravva, P., Gastonguay, M.R., French, J.L., Tensfeldt, T.G. & Faessel, H.M. Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin. Pharmacol. Ther. 87, 336-344 (2010).
16. Mould, D.R. et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin. Pharmacol. Ther. 86, 190-196 (2009).
17. T othfalusi, L., Speidl, S. & Endrenyi, L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br. J. Clin. Pharmacol. 65, 110-122 (2008). (Pubitemid 350265172)
18. H?in, E. et al. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin. Pharmacol. Ther. 85, 418-425 (2009).
19. Ito, K., Hutmacher, M., Liu, J., Qiu, R., Frame, B. & Miller, R. Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder. Clin. Pharmacol. Ther. 84, 127-135 (2008). (Pubitemid 351861494)
20. Zingmark, P.H., Kedal, M. & Karlsson, M.O. Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. J. Pharmacokinet. Pharmacodyn. 32, 261-281 (2005).
21. Lacroix, B.D., Lovern, M.R., Stockis, A., Sargentini-Maier, M.L., Karlsson, M.O. & Friberg, L.E. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 86, 387-395 (2009).
22. Passchier, J. et al. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 64, 542-549 (2010).
23. Searle G. et al. A pseudo-reference region method applied to measurement of GlyT1 occupancy in human brain using [11C]GSK931145 and PET (abstract). Eighth Annual Symposium on Functional Neuroreceptor Mapping of the Living Brain (NRM), Glasgow, March 2010.
24. Beal, S.L., & Sheiner L.B. NONMEM User's Guide. (NONMEM Project Group, University of California, San Francisco, CA, 1992).
25. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17-20 (2007). (Pubitemid 46944205)